Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma.
Rendo V, Lee EQ, Bossi C, Khuu N, Rudek MA, Pal S, Reynolds ARN, Fassinou ACR, Ayoub G, Lapinskas E, Pisano W, Jeang J, Stopka SA, Regan MS, Spetz J, Desai A, Lieberman F, Fisher JD, Pelton K, Huang RY, Nabors LB, Holdhoff M, Danda N, Strowd R, Desideri S, Walbert T, Ye X, Agar NYR, Grossman SA, Alexander BM, Wen PY, Ligon KL, Beroukhim R.
Rendo V, et al. Among authors: khuu n.
medRxiv [Preprint]. 2024 Aug 14:2024.08.12.24311893. doi: 10.1101/2024.08.12.24311893.
medRxiv. 2024.
PMID: 39211865
Free PMC article.
Preprint.